AZN
AstrazenecaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
AZN Profile
Astrazeneca Plc
A global, innovation-driven biopharmaceutical leader developing and commercializing medicines for various diseases
Pharmaceutical
06/17/1992
09/28/2020
NASDAQ Stock Exchange
94,300
12-31
Depository Receipts (Ordinary Shares)
1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge, CB2 0AA England
Development and sales of prescription drugs such as cardiovascular and digestive system infections, neuro-oncology, respiratory inflammation, etc
AstraZeneca AG was incorporated in England and Wales on 17 June 1992 under the Companies Act 1985. The company was formed in 1993 when Imperial Chemical Industries spun off its pharmaceutical, agrochemical and specialty chemicals businesses. In 1999, the company sold its specialty chemicals business. Also in 1999, the company merged with the Swedish company Astra. In 2000, the company spun off its agrochemical business and merged it with a similar business of Novartis to form a new company, Syngenta AG. In 2007, the Group acquired MedImmune, a biologics and vaccine company based in the United States. In 2021, the Group acquired Alexion, a rare disease company based in the United States.
